arsenic trisulfide has been researched along with Angiogenesis, Pathologic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, Y; Chen, S; Feng, Z; Kang, T; Lu, S; Zhu, C | 1 |
| Chen, S; Ding, W; Kim, S; Pan, M; Tong, Y; Zhang, L; Zhang, X | 1 |
2 other study(ies) available for arsenic trisulfide and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Arsenic Sulfide Inhibits Hepatocellular Carcinoma Metastasis by Suppressing the HIF-1α/VEGF Pathway.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Human Umbilical Vein Endothelial Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Liver Neoplasms; Neovascularization, Pathologic; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2023 |
Arsenic sulfide inhibits cell migration and invasion of gastric cancer in vitro and in vivo.
Topics: Animals; Antigens, CD; Antineoplastic Agents; Arsenicals; beta Catenin; Cadherins; Cell Adhesion; Cell Line, Tumor; Cell Movement; Dose-Response Relationship, Drug; Humans; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Neoplasm Metastasis; Neovascularization, Pathologic; Signal Transduction; Sp1 Transcription Factor; Stomach Neoplasms; Sulfides; Time Factors; Tumor Burden; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2015 |